Formula I SARS-CoV-2 Main Protease Inhibitors for Broad Coronavirus Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds and methods to effectively treat and prevent viral infections, particularly those caused by coronaviruses, which mutate easily and can spread between animals and humans, leading to infectious-disease outbreaks.
Innovation Solution
Development of a compound of Formula (I) and its pharmaceutically acceptable salts, which can be used in pharmaceutical compositions to treat or prevent viral infections, including coronaviridae infections, by targeting specific molecular structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments are used, then viral infections can be treated, but coronaviruses mutate easily leading to treatment resistance and outbreaks
Solution Approach 1:
The patent employs parameter changes by modifying chemical structures (Formula I compounds with varying R1, R2, R3, R4 substituents) to create multiple antiviral agents with different properties. This allows adaptation to different viral mutations while maintaining core inhibitory activity against SARS-CoV-2 main protease.
Solution Approach 2:
The compounds of Formula (I) are designed with a core structure that provides universal activity against coronaviruses, including SARS-CoV-2. The main protease inhibition mechanism is conserved across different viral strains, making the compound family broadly effective despite viral mutations.
2Reliability
If new antiviral compounds are developed to target specific molecular structures, then treatment effectiveness improves, but development time and complexity increase
Solution Approach 1:
The patent segments the antiviral compound into a core structure (Formula I) and variable substituents (R1-R4 groups). This modular approach allows systematic optimization of different regions independently, accelerating development by focusing on key structural elements that provide both activity and drug-like properties.
Solution Approach 2:
The patent performs preliminary structure-activity relationship analysis by designing compounds with specific functional groups and structural features before full development. This preliminary optimization of the core structure and substituents reduces later development iterations and speeds up the path to effective antivirals.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.